This is what Franck Lescure, a partner at VC firm Auriga Partners, told me when I met him in Paris at his office next to the Champs-Elysées. Their last fund, Auriga IV Bioseeds, focuses on infectious disease and microbiology, with 6 investments so far and 9 by the end of 2016. It was a great way to catch up and understand better what makes Auriga unique (or not).
Auriga has been founded in 1993 and has raised 5 funds so far (over €390M in total) both in life sciences and information technologies. It supported some of the French biotech success stories including Innate-Pharma, Nicox, Erytech and many more. Auriga IV Bioseeds represents €43M, coming from the French government (FNA), the European Investment fund (EIF), several industry players (Pfizer, Sanofi-Pasteur, MSD, Miraca) and other institutions.
To be honest, this didn’t seem so unique to me compared to other specialised early-stage investors in Europe or in France, as for example Sofinnova,